WMT develops treatments for cancer and chronic inflammatory conditions using a novel principle: Induction of the ER/ISR stress response through potent small molecules! Our ER/ISR stress induces hit preferentially rapidly dividing and metabolically very active cells, i.e. cancer cells and highly activated immune cells. For cancer applications we have elected a clinical candidate, B-306, where we can demonstrate efficacy in various animal models, syngeneic and xenograft, up to 28 days. We plan for IND filing for a first Phase I study in solid cancers (targets are ovarian, urothelial, renal, pancreas and liver) within 15 months upon availabilizty of funding. We seek for venture or private funding to raise 10M Euros+ for entry into clinical development.